![]() ![]() Rooted in science and providing reliable and user-friendly solutions, it bridges the gap between academic ideas and clinical use. Founded in 2014 by female scientist Eva van Rikxoort, the company develops highly innovative deep learning solutions for lung and retinal image analysis. Thirona partners with research institutions and medical companies in their innovation trajectories aimed to enable breakthroughs in treatment development and clinical care. Thirona is an innovative company specializing in artificial intelligence for medical image analysis that allow for precise quantification of disease symptoms and contribute to personalized patient treatment. Partnerships based on a shared vision and mutual trust are very centric to Thirona’s strategy, so we are happy to have iCare as our strategic partner”, says Diederik Sakkers, business development manager RetCAD at Thirona. iCare is not just a distribution channel for us. “By joining forces with iCare we can bring innovation to the mainstream markets faster. RetCAD™ is already distributed worldwide through integration partnerships with major fundus camera vendors such as Topcon, Canon, Tomey and Nidek, as well as medical solutions providers such as Delft Imaging. Seamless integration of RetCAD™ into the iCare platform enables an optimal user experience, with test results instantly presented in a form of simple visualization, meaningful for the patient”, says Mark van Grinsven, head of Retina division at Thirona. “Combining high quality of iCare’s fundus images with RetCAD’s reliability of automated analysis, together we can provide eye care practitioners with a powerful trustworthy solution, enabling them screening more patients faster. Simplified visualization of the examination analysis with heat maps supports eye care providers in validating the AI results and helps improve patient engagement in the prevention of severe eyesight problems and blindness. Having every patient fundus examination instantly analyzed with a clinically validated software system, initial screening procedures can be done more efficiently and at least as accurate as when conducted by human experts. High-quality images from the iCare DRSplus fundus imaging system provide a good foundation for the solution” says Pirjo Kortteisto, business development manager of Icare Finland. We start by screening diabetic retinopathy from diabetics and bring to market an integrated service that is fast and easy to use thanks to automation. Together with Thirona, we are implementing a top-performance screening solution based on fundus images. ”This is an exciting opportunity to contribute to keeping the wonderful world visible for all. Icare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. ICare is part of Revenio, a leading company in the global market for ophthalmological devices and software solutions. The partnership underpins both companies’ technological leadership in this field. ![]() Nijmegen, the Netherlands (April 27th, 2022) – Thirona, one of the leading companies specializing in artificial intelligence for medical image analysis, has signed a strategic partnership agreement with iCare, for the implementation of Thirona’s RetCAD™ artificial intelligence software into the iCare solutions for eye disease screening, in Europe. ![]()
0 Comments
Leave a Reply. |